About: BCX4430 – a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: BCX4430 – a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	BCX4430 – a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease
Creator	Bavari, Sina Warren, Travis Julander, Justin Babu, Yarlagadda Kotian, Pravin Panchal, Rekha Sheridan, William Taubenheim, Brian Dobo, Sylvia El-Kattan, Yahya Rose, Angela Taylor, Raymond
Source	Elsevier; Medline; PMC
abstract	The adenosine nucleoside analog BCX4430 is a direct-acting antiviral drug under investigation for the treatment of serious and life-threatening infections from highly pathogenic viruses, such as the Ebola virus. Cellular kinases phosphorylate BCX4430 to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug’s monophosphate nucleotide into the growing RNA chain, causing premature chain termination. BCX4430 is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV and SARS-CoV. In vivo, BCX4430 is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, BCX4430 has demonstrated pronounced efficacy. In experiments conducted in several models, both a reduction in the viral load and an improvement in survival were found to be related to the dose of BCX4430. A Phase 1 clinical trial of intramuscular administration of BCX4430 in healthy subjects is currently ongoing.
has issue date	2016-05-01(xsd:dateTime)
bibo:doi	10.1016/j.jiph.2016.04.002
bibo:pmid	27095300
has license	gold-oa
sha1sum (hex)	703f86c62ceb141bb69656ce5d3ae330d0969976
schema:url	https://doi.org/10.1016/j.jiph.2016.04.002
resource representing a document's title	BCX4430 – a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease
has PubMed Central identifier	PMC4937725
has PubMed identifier	27095300
schema:publication	Journal of Infection and Public Health
resource representing a document's body	covid:703f86c62ceb141bb69656ce5d3ae330d0969976#body_text
is schema:about of	named entity 'triphosphate' named entity 'viral load' named entity 'improvement' named entity 'BCX4430' named entity 'chain termination' named entity 'oral administration' named entity 'BCX4430' named entity 'TREATMENT' named entity 'IN VIVO' named entity 'PATHOGENIC' named entity 'FILOVIRUSES' named entity 'INTRAMUSCULAR ADMINISTRATION' named entity 'VIRAL PATHOGENS' named entity 'RNA' named entity 'VARIETY' named entity 'EXPERIMENTS' named entity 'ATP' named entity 'SARS-COV' named entity 'VIRUSES' named entity 'DEMONSTRATED' named entity 'EFFICACY' named entity 'BCX4430' named entity 'GROWING' named entity 'INVOLVING' named entity 'LETHAL' named entity 'STUDIES' named entity 'SURVIVAL' named entity 'PHASE 1 CLINICAL TRIAL' named entity 'INFECTIONS' named entity 'NUCLEOTIDE' named entity 'ONGOING' named entity 'CELLULAR' named entity 'EBOLA VIRUS DISEASE' named entity 'IN VITRO' named entity 'INFECTIOUS AGENTS' named entity 'IS A' named entity 'DRUG' named entity 'EXPERIMENTAL' named entity 'LIFE-THREATENING INFECTIONS' named entity 'IMPROVEMENT' named entity '27S' named entity 'INTRAMUSCULAR' named entity 'FOUND' named entity 'ACTIVE' named entity 'INTRAPERITONEAL' named entity 'CHAIN TERMINATION' named entity 'ADENOSINE' named entity 'TRIPHOSPHATE' named entity 'CURRENTLY' named entity 'REDUCTION' named entity 'CAUSING' named entity 'MIMICS' named entity 'NUCLEOSIDE ANALOG' named entity 'VIRAL RNA' named entity 'POLYMERASES' named entity 'MERS-COV' named entity 'KINASES' named entity 'TREATMENT' named entity 'DIRECT' named entity 'ORAL ADMINISTRATION' named entity 'DOSE' named entity 'VIRAL LOAD' named entity 'INCLUDING' named entity 'HEALTHY SUBJECTS' named entity 'RIFT VALLEY FEVER VIRUS' named entity 'RNA CHAIN' named entity 'MODELS' named entity 'MARBURG VIRUS' named entity 'INVESTIGATION' named entity 'PREMATURE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software